2026. ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study. Italian Journal of Medicine. 20, s1 (May 2026). DOI:https://doi.org/10.4081/.